Science Explorer Back to mapMap
Discussion
Institution · Centre Hospitalier de Perpignan

Most cited papers from Centre Hospitalier de Perpignan

Centre Hospitalier de Perpignan

What are the most cited papers from Centre Hospitalier de Perpignan?

The most cited paper from Centre Hospitalier de Perpignan is "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (Thierry Conroy, Françoise Desseigne, Marc Ychou et al., 2011), with 7,927 citations. Next come "FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer" (2,918) and "Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis" (473).

Showing 50 of 60 papers. Every paper with more than 75 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine Open access 11 May 2011 7,927
2 FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Thierry Conroy et al. · New England Journal of Medicine Open access 19 Dec 2018 2,918
3 Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis Eva Maria Herrmann et al. · Hepatology Open access 31 Mar 2017 473
4 Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients* Sophie Georgin‐Lavialle et al. · British Journal of Dermatology Open access 11 Oct 2021 434
5 Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial The ABDOMIX Group, Didier M. Payen, Joëlle Guilhot et al. · Intensive Care Medicine Open access 10 Apr 2015 410
6 Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial C. Carrié et al. · The Lancet Oncology 8 May 2016 364
7 The open abdomen in trauma and non-trauma patients: WSES guidelines Federico Coccolini et al. · World Journal of Emergency Surgery Open access 2 Feb 2018 353
8 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology 11 Jun 2013 343
9 The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe Joren Maeremans et al. · Journal of the American College of Cardiology Open access 24 Oct 2016 314
10 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections Massimo Sartelli et al. · World Journal of Emergency Surgery Open access Dec 2018 307
11 Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study Caroline Houillier et al. · Journal of Clinical Oncology 20 Feb 2019 285
12 Intraspinal meningiomas: Review of 54 cases with discussion of poor prognosis factors and modern therapeutic management François‐Xavier Roux, F. Nataf, Magloire Pinaudeau et al. · Surgical Neurology Nov 1996 275
13 Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial C. Carrié et al. · The Lancet Oncology Open access 16 Oct 2019 261
14 Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification Gaël Nicolas et al. · Brain 21 Sep 2013 242
15 Evolutionary Relationships and Biogeography of Biomphalaria (Gastropoda: Planorbidae) with Implications Regarding Its Role as Host of the Human Bloodfluke, Schistosoma mansoni Randall J. DeJong et al. · Molecular Biology and Evolution Open access Dec 2001 213
16 High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes Laurent Bonello, Michel Pansiéri, Julien Mancini et al. · Journal of the American College of Cardiology Open access Jul 2011 209
17 Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial Thorsten Braun et al. · Blood Open access 9 Aug 2011 199
18 High total metabolic tumor volume at baseline predicts survival independent of response to therapy Laëtitia Vercellino et al. · Blood Open access 24 Jan 2020 187
19 Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone Pierre Seners et al. · JAMA Neurology Open access 14 Jan 2021 184
20 A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study Roland Richard Tilz et al. · European Heart Journal Open access 16 Apr 2023 170
21 Long‐term assessment of neuropsychiatric adverse reactions associated with efavirenz Pierre Lochet, Hélène Peyrière, Anne Lotthé et al. · HIV Medicine Open access 2003 168
22 Primary Angiitis of the Central Nervous System: Description of the First Fifty‐Two Adults Enrolled in the French Cohort of Patients With Primary Vasculitis of the Central Nervous System Hubert de Boysson, Mathieu Zuber, Olivier N. Naggara et al. · Arthritis & Rheumatology 8 Jan 2014 160
23 Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM) Sylvain Thépot, Raphaël Itzykson, Valérie Seegers et al. · Blood 28 Jul 2010 157
24 The early days of IVF outside the UK Jean J. Cohen, Alan Trounson, Karen Dawson et al. · Human Reproduction Update 27 May 2005 147
25 Neurologic manifestations associated with COVID-19: a multicentre registry Elodie Meppiel et al. · Clinical Microbiology and Infection Open access 13 Nov 2020 143
26 Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab Anthony J.J. Dohan et al. · Gut 17 May 2019 139
27 Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study Jean–Marc Phelip et al. · Journal of Clinical Oncology 18 Oct 2021 135
28 Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening Dirkje S. Postma, C. Sevette, Y. Martinat et al. · European Respiratory Journal Open access Jun 2001 133
29 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier B. Pivot et al. · The Lancet Open access346 authors Jun 2019 129
30 Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: A large multicentre audit with real-life results Dominique Thabut et al. · Journal of Hepatology 14 Sep 2017 127
31 Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences Rosa Vargas‐Poussou et al. · The Journal of Clinical Endocrinology & Metabolism Open access 10 Mar 2016 127
32 Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrel Laurent Bonello, Julien Mancini, Michel Pansiéri et al. · Journal of Thrombosis and Haemostasis Open access 3 Aug 2012 127
33 Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians—Results of the NutriCancer2012 Study Emmanuel Gyan, Bruno Raynard, Jean‐Philippe Durand et al. · Journal of Parenteral and Enteral Nutrition 31 Jan 2017 125
34 Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications D. Cowen, E. Groß, Philippe Rouannet et al. · Breast Cancer Research and Treatment Open access 27 Apr 2010 125
35 Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion Andréa Toma et al. · Leukemia Open access 26 Oct 2015 122
36 Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma Jean–Louis Jouve, Thierry Lecomte, Olivier Bouché et al. · Journal of Hepatology Open access 21 May 2019 117
37 Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) Thomas Aparicio et al. · Annals of Oncology Open access 21 Oct 2015 113
38 Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera Émilien Delmont et al. · Journal of Neurology Open access 16 Jul 2020 112
39 Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study Stéphane Nahon, Hervé Hagège, Jean‐Paul Latrive et al. · Endoscopy 29 Oct 2012 111
40 Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study Caroline Houillier et al. · Journal of Clinical Oncology 14 Jul 2022 108
41 Good Syndrome: An Adult-Onset Immunodeficiency Remarkable for Its High Incidence of Invasive Infections and Autoimmune Complications Marion Malphettes, Laurence Gérard, Lionel Galicier et al. · Clinical Infectious Diseases 31 Mar 2015 105
42 A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK) Shohreh Honarbakhsh et al. · JACC. Clinical electrophysiology Open access 28 Oct 2020 96
43 Epileptic electroencephalographic abnormalities and developmental dysphasias: A study of 32 patients Bernard Échenne, Renée Cheminai, François Rivier et al. · Brain and Development Jul 1992 95
44 VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation Olivier Kosmider et al. · Nature Communications Open access 30 Jan 2024 93
45 Utility of Intravascular Ultrasound in Percutaneous Revascularization of Chronic Total Occlusions Alfredo Ruggero Galassi, Satoru Sumitsuji, Marouane Boukhris et al. · JACC: Cardiovascular Interventions Open access Oct 2016 92
46 del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma Jill Corre et al. · Blood Open access 20 Oct 2020 91
47 Validation of the revised international prognostic scoring system ( IPSS ‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS ( EUMDS ) registry Louise de Swart et al. · British Journal of Haematology Open access 24 Apr 2015 91
48 Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000 Marie-Anne Vandenhende, Caroline Roussillon, Sandrine Hénard et al. · PLoS ONE Open access 17 Jun 2015 90
49 Molecular and clinical diversity in primary central nervous system lymphoma Isaias Hernández-Verdín et al. · Annals of Oncology Open access 17 Nov 2022 88
50 Malignant Adenomyoepithelioma of the Breast: An Immunohistochemical, Cytophotometric, and Ultrastructural Study of a Case with Lung Metastases Monique Trojani, Michel Guiu, Hélène Trouette et al. · American Journal of Clinical Pathology Dec 1992 87

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.